Scientific Aspects and Clinical Signs of Muscle Pain—Three Years Later

REFERENCES

• Pongratz D, Vorgerd M, Schoser B GH. Scientific aspects and clinical signs of muscle pain. J Musculoskel Pain. 2004; 12: 121–128
   Web of Science ®Google Scholar
• Engel A G. Franzini-Armstrong C: Myology. 3^rd ed., vols. 1 and 2. McGraw-Hill, Inc., New YorkUSA 2004
   Google Scholar
• Karpati G. Structural and Molecular Basis of Skeletal Muscle Diseases. Blackwell Publishing, Basel, Swiss 2006
   Google Scholar
• Karpati G, Hilton-Jones D, Griggs R G. Disorders of voluntary muscle. Oxford University Press, New YorkUSA 2001
   Google Scholar
• Figarella-Branger D, Civatte M, Bartoli C, Pellissier J F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle & Nerve 2003; 28: 659–682
   PubMed Web of Science ®Google Scholar
• Dalakas M C, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 1762–1763
   PubMedGoogle Scholar
• Wolfsdorf J I, Weinstein D A. Glycogen storage diseases. Rev Endocr Metab Disord 2003; 4: 95–102
   PubMed Web of Science ®Google Scholar
• Vorgerd M, Zange J. Carbohydrate oxidation disorders of skeletal muscle. Curr Opin Clin Nutr Metab Care 2002; 5: 611–617
   PubMedGoogle Scholar
• Rommel O, Kley R A, Dekomien G, Epplen J T, Vorgerd M, Hasenbring M. Muscle pain in myophosphorylase deficiency (McArdle's disease): The role of gender, genotype, and pain-related coping. Pain 2006; 124: 295–304
   PubMed Web of Science ®Google Scholar
• Delorme T, Boureau F, Eymard B, Laforet P, Cottrel F. Clinical study of chronic pain in hereditary myopathies. Eur J Pain. 2004; 8: 55–61
   PubMedGoogle Scholar
• Bushby K MD, Pollitt C, Johnson M A, Rogers M T, Chinnery P F. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): Four illustrative case reports. Neuromusc Dis 1998; 8: 574–579
   PubMedGoogle Scholar
• Griggs R C, Karpati G. Muscle pain, fatigue and mitochondriopathies. N Engl J Med 1999; 314: 1077–1078
   Google Scholar
• Schara U, Schoser B GH. Myotonic Dystrophies type 1 and 2—a summary of current aspects. Semi Pediat Neurol 2006; 13: 71–79
   PubMedGoogle Scholar
• George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal Pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938–1942
   PubMedGoogle Scholar
• Tiffreau V, Viet G, Thevenon A. Pain in neuromuscular disease. Am J Phy Med Rehabil 2006; 85: 756–766
   PubMed Web of Science ®Google Scholar
• Betz R C, Schoser B G, Kasper D, Ricker K, Ramírez A, Stein V, Torbergsen T, Lee Y-A, Nöthen M M, Wienker T, Malin J-P, Propping P, Reis A, Mortier W, Jentsch T J, Vorgerd M, Kubisch C. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001; 28: 218–219
   PubMed Web of Science ®Google Scholar
• Kubisch C, Schoser B G, von During M, Betz R, Goebel H H, Zahn S, Ehrbrecht A, Aasly J, Schroers A, Popovic N, Lochmüller H, Schröder H J, Malin J-P, Fricke B, Meinck H-M, Torbergsen T, Engels H, Voss B, Vorgerd M. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 2003; 53: 512–520
   PubMed Web of Science ®Google Scholar
• Woodman S E, Sotgia F, Galbiati F, Minetti C, Lisanti M P. Caveolinopathies: Mutations in caveolin 3 cause four distinct autosomal dominant muscle diseases. Neurology 2004; 62: 538–543
   PubMed Web of Science ®Google Scholar
• Schoser B GH, Hilton-Jones D, Müller-Felber W, Kubisch C, Toscano A, Vincent A, van den Berg P. Immune-mediated rippling muscle disease with myasthenia gravis: A report of 7 patients. Neuromuscl Dis 2006; 16: 647
   Google Scholar
• Gerwin R D. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep 2001; 5: 412–420
   PubMedGoogle Scholar
• Simons D, Dommerholt J. Myofascial trigger points and myofascial pain syndrome: A critical review of recent literature. J Man Manipul Therapy 2006; 14: E124–171
   Google Scholar
• Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach F W, Jensen T S. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006; 67: 241–245
   PubMedGoogle Scholar
• Gobel H, Heinze A, Reichel G, Hefter H, Benecke R. Dysport myofascial pain study group: Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study. Pain 2006; 125: 82–88
   PubMed Web of Science ®Google Scholar
• Graboski C L, Gray D S, Burnham R S. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain 2005; 118: 170–175
   PubMed Web of Science ®Google Scholar
• Ho K Y, Tan K H. Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review. Eur J Pain 2006, in press, published online
   PubMedGoogle Scholar
• Dommerholt J, Myoral del Moral O, Gröbli C. Trigger point dyr needling. J Manual Manipul Therap 2006; 14: E70–87
   Google Scholar
• Buskila D, Sarzi-Puttini P, Ablin J N. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007; 8: 67–74
   PubMed Web of Science ®Google Scholar
• Gracely R H, Geisser M E, Giesecke T, Grant M A, Petzke F, Williams D A, Clauw D J. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127: 835–843
   PubMed Web of Science ®Google Scholar
• Arnold L M, Rosen A, Pritchett Y L, D'Souza D N, Goldstein D J, Iyengar S, Wernicke J F. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15
   PubMed Web of Science ®Google Scholar
• Crofford L J, Rowbotham M C, Mease P J, Russell I J, Dworkin R H, Corbin A E, Young J P, Jr, La Moreaux L K, Martin S A, Sharma U. Pregabalin 1008-105 Study Group: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264–1273
   PubMed Web of Science ®Google Scholar
• Lawson K. Emerging pharmacological therapies for fibromyalgia. Curr Opin Investig Drugs 2006; 7: 631–636
   PubMed Web of Science ®Google Scholar
• Scharf M B, Baumann M, Berkowitz D V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003; 30: 1070–1074
   PubMed Web of Science ®Google Scholar